From funding innovative research to advocating for government action to providing a support structure for our community, no other organization does more to fight type 1 diabetes (T1D) than JDRF.
Our research investments deliver on the promise of making life with Type 1 Diabetes better. We’ve championed technology with that goal in mind, from the first engineered insulin 40 years ago to recent advancements like artificial pancreas systems and more.
Our powerhouse team in Washington, D.C., works with volunteers across the country to secure government support for innovative Type 1 Diabetes research. Meanwhile, our experts collaborate with regulators and health plans to help the entire community benefit from treatments and therapies.
"JDRF has supported me in many ways in various aspects throughout my life. It’s not just about raising funds and advancing science, it’s about supporting families. It’s about advocacy and getting CGM [continuous glucose monitoring] approved for the Medicare population. And it’s about this amazing network of individuals, who are brought together for a joint cause they are passionate about.”
Jennifer Sherr, M.D., Ph.D., Yale School of Medicine, JDRF-funded Researcher
The Outlook has Never Been Better
JDRF has changed the way we live with T1D. Everyday, we are learning more about the disease in an effort to end it once and for all.
Less than 50 years ago, insulins were derived from animals, and dosing was wildly inconsistent.
Synthetic insulins with a range of speeds and durations offer the precision and flexibility to better balance blood-sugar levels.
50 years ago, a prototype insulin pump was so large it had to be worn like a backpack.
Compact insulin pumps fit easily in a pocket—and they’ve gotten smarter too.
30 years ago, there was no way to predict if someone would develop T1D.
It is possible to detect T1D before symptoms arise, avoiding adverse side effects.
Beta Cell Biology
For decades, experts believed that beta cells stopped functioning altogether within a few years of T1D onset.
We know beta cells continue to function even after decades with T1D, and it might be possible to cure T1D by preserving or expanding these beta cells.
Diabetic Eye Disease
35 years ago, the risk of vision loss from diabetic eye disease was 50 percent.
State-of-the-art care has cut the risk to 5 percent, and therapies to eliminate the remaining risk are in development.
You Too Can Make a Difference
Without clinical trial volunteers, promising new therapies can’t get approved, and into the hands of people who need them. You can help by participating in a trial near you.
Leveraging Our Leadership: Increased Support for T1D Research
Through our advocacy and research leadership, JDRF influences and attracts others to support funding for cures and improving lives. For every dollar that JDRF puts towards research, we pull in nearly $2.50 more. In fiscal year 2019, that totaled $414.5M.
JDRF | $121.5 million
JDRF supporters helped raise $106.1M to fund JDRF research grants. In addition, the JDRF T1D Fund invested $15.4M in in small, T1D-focused companies.
NGOs and Foundations | $31 million
JDRF works with other organizations to secure their support for key T1D programs. Some partner with us to invest funding or do so on their own based on our leadership.
Industry Partners | $80 million
We collaborate with hundreds of industry partners – including pharmaceutical and technology companies – who also invest in T1D research.
Governments | $182 million
JDRF advocates for additional funding from the United States government and international governments. Through the Federal Special Diabetes Program, JDRF secures $150M annually from the U.S. government.
Watch Your Gift Grow
Your donation to JDRF is the crucial first step in the quest for a cure.